20 miliardi di euro l’anno: i costi per il cancro in Italia – Prevenzione attiva, la vera arma vincente
IMMUNEBALANCE assesses the immune system imbalance, as a part of the HELIXAFE prevention model. Colorectal cancer formation and progression, like any other solid cancer, rely on the cancer cell’s ability to bypass the immune response. This ability depends on genetic, epigenetic, and phenotypic changes that mask tumor cells from immune system recognition. Nevertheless, the immune system remains a potent inhibitor of cancer growth, and many cells that could give rise to cancer are efficiently eliminated by immune defenses before tumor development. Several factors influence this activity, including gender, eating habits, physical activity, and age – the latter being a very important risk factor for colorectal cancer development. IMMUNEBALANCE enables the monitoring of the immune balance in health people, regardless of their age, to detect possible imbalances that can be corrected via lifestyle-based solutions to help reduce the risk of neoplastic diseases.
